semaglutide gut microbiome microbiota and metabolic disease risk in youth: Cell Reports Medicine Frontiers | Multi-omics profiling implicates

Key Takeaways Pancreatitis affects roughly 0.3% of semaglutide users in clinical trials, far less common than nausea, which affects over 40%

Do not waste weeks wondering if your protocol is failing when the answer might be sitting in a warm vial

Tirzepatide was initially approved for type 2 diabetes (Mounjaro), and it is now also approved for long-term weight loss in adults with obesity or overweight with weight-related health conditions (Zepbound)

Intranasal administration of Ex-4 at a dose of 0.5 g/kg daily for 7 days before MCAO in mice, rather than intraperitoneal administration at an equivalent dose, exerted neuroprotective effect by reducing infarct volume and neurological deficits which were blocked by knocking down GLP-1 receptor with shRNA (97)

FEBS Lett 97(1):138140

Slow vs fast titration compared at matched final maintenance dose for both 4 mg and 8 mg cohorts